Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis Pharmaceuticals A/S announces NDA submission for Envarsus in Kidney Transplant Recipients

Monday, 30 Dec 2013 03:00am EST 

Veloxis Pharmaceuticals A/S:Says submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus for the prevention of organ rejection in kidney transplant recipients.